Agenda

Download 2022 Brochure
Flip through our 2022 conference brochure and discover what’s new this year.
- Jump to:
- At a Glance
- Day 1
- Day 2
- Print-friendly Format
Day 1 - Thursday, January 20, 2022
Day 2 - Friday, January 21, 2022
Day 1 - Thursday, January 20, 2022
8:45 |
Co-Chairs’ Opening Remarks![]() Alexis Sciuk ![]() Farah Husein |
9:00 |
Opening KeynoteLight at the End of the Tunnel—Yes or No? Examining What it Will Take to Build a More Resilient, Patient-Driven Health Care System in Canada![]() Louise Binder |
9:30 |
Forecasting Time-to-Listing Amid the Pandemic: What to Expect and How to Mitigate Delays in the CADTH Review and pCPA Negotiation Process![]() Brent Fraser ![]() Dominic Tan
|
10:30 |
Break |
11:00 |
Innovative Contracting and Drug Pricing: How to Build a More Agile Reimbursement System in Canada![]() Andrea Masters ![]() Sang Mi Lee ![]() Brad Groves There have been successful innovative agreements and examples of agility in the Canadian pathway to access for innovations. However, there is a lack of sharing the learnings and no guidance for industry in terms of the characteristics or scenarios where innovative agreements are of value to payors and patients. More transparency, empathy and collaboration across all stakeholders is necessary to identify and achieve shared outcomes around building a more agile reimbursement pathway in Canada. This session will explore:
|
12:00 |
How to Navigate Exceptions to the Co-Pay Ban under Bill 92 in Quebec![]() Mathieu Gagné The Government of Quebec has published the final regulation restricting financial assistance to patients for drugs covered under Quebec’s basic plan. To avoid running afoul of the regulation, manufacturers will need to reassess current activities within the context of the ban and gain clarity on where exceptions will apply. This session will cover:
|
12:45 |
1:1 Networking |
1:00 |
Break |
1:30 |
How to Optimize Data and Health Resources to Support Patient Centred Decision-Making on New and Innovative Therapies![]() Laurie Lambert ![]() Nicole Yada ![]() Mina Tadrous ![]() Dr. Scott Klarenbach
|
2:30 |
Key Industry Learnings and Good Practices Gleaned from Experienced pCPA Negotiators![]() Chad Jarema
|
3:00 |
Break |
3:30 |
PMPRB Implications and Takeaways for Companies![]() Eileen McMahon ![]() Wayne Critchley ![]() Neil Palmer
|
4:30 |
Conference Adjourns |
Day 2 - Friday, January 21, 2022
8:50 |
Co-Chair Opening Remarks![]() Alexis Sciuk ![]() Farah Husein |
9:00 |
Fireside Chat: The Vision for CADTH 2022 and BeyondHow HTA & HTM is Evolving and the Implications for Canada’s Health System and its Stakeholders![]() Suzanne McGurn Moderator:![]() Alexis Sciuk In July 2020, Ms. Suzanne McGurn stepped into the role of President and CEO of CADTH. This session will focus on lessons and insights from the first 18 months at the helm, amid immense change sparked by the pandemic. Learn how CADTH has responded and continued to be “Driven by the Evidence” during this turbulent time, the agency’s top priorities for 2022 and how it will be engaging with industry.
|
9:30 |
Scaling up Canada’s Life Sciences Sector: How to Attract Investment and Retain Talent![]() Andrew Casey ![]() Dr. Sheila Singh ![]() Jason Field Moderator:![]() Pamela Fralick
|
10:30 |
Break |
11:00 |
Journey Mapping: What the Patient Experience Reveals about Pathways to Access & Reimbursement![]() Durhane Wong-Rieger In this session, Canadians living with a rare disorder will share their personal journey from the point of diagnosis through to drug access and reimbursement. A focus will put on:
|
11:45 |
Case StudyAnalysis of Biosimilars in Canada: How have Switch Policies Impacted Drug Spending and Health Outcomes![]() Dr Tijana Fazlagic Ontario, Quebec, and other provinces across Canada have announced that they will follow British Columbia’s lead in pursuing their own non-medical switch policies for biosimilars. There has been extensive discussion about the impact on patients, who are already stable on a biologic as well as the opportunity for significant cost savings should biosimilars achieve similar therapeutic results. B.C. completed its phased approach to switching patients in October. This session will explore:
|
12:15 |
1:1 Networking |
12:30 |
Break |
1:00 |
Case StudyHow Stakeholders Collaborated to Achieve Timely Patient Access and Reimbursement for an Innovative Cystic Fibrosis Treatment![]() Dr. Mark Chilvers ![]() Chris McLeod Expediting patient access for new, innovative treatments for rare diseases continues to be a challenge in Canada. The review and negotiation periods can be long and arduous for stakeholders who are working diligently to ensure safety and efficacy, while also grappling with the question of affordability. However, a newly developed cystic fibrosis treatment, lauded as life-sustaining for patients, secured a priority review by Health Canada, a recommendation from CADTH and successful pricing negotiations leading to PLAs for public reimbursement in several provinces. This session will examine:
|
1:45 |
Top 3 Trends in the Private Payer Landscape that Could Impact your Market Access Strategy![]() Joan Weir ![]() Jayson Gallant Moderator:![]() Farah Jivraj
|
2:30 |
Break |
3:30 |
Where Patent Protection Intersects with Market Entry Decisions: How to Set Your Organization’s Access Strategy Up for Success in 2022![]() Daphne Lainson
|
4:15 |
The Latest in U.S. Drug Pricing Reform and the Implications for Canadian Companies![]() Trevor Wear This session will examine the where proposals on drug pricing reform have landed and the implications for manufacturers.
|
5:00 |
Conference Adjourns |